https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-10-09 / Br. J. Cancer 2007 Nov;97(9):1251-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-10-09 / Br. J. Cancer 2007 Nov;97(9):1251-92007-10-09 00:00:002019-02-15 08:50:17Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-09-24 / Cancer Sci. 2007 Dec;98(12):1930-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-09-24 / Cancer Sci. 2007 Dec;98(12):1930-52007-09-24 00:00:002019-02-15 08:48:20Regression of intestinal adenomas by vaccination with heat shock protein 105-pulsed bone marrow-derived dendritic cells in Apc(Min/+) mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-08-15 / Cancer Res. 2007 Aug;67(16):7798-806
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-08-15 / Cancer Res. 2007 Aug;67(16):7798-8062007-08-15 00:00:002019-02-15 08:48:34Localized hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-08-01 / Cancer Res. 2007 Aug;67(15):7477-86
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-08-01 / Cancer Res. 2007 Aug;67(15):7477-862007-08-01 00:00:002019-02-15 08:50:19A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-06-08 / Vaccine 2007 Aug;25(32):6037-46
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-06-08 / Vaccine 2007 Aug;25(32):6037-462007-06-08 00:00:002023-01-23 10:34:42Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-06-01 / Int. J. Cancer 2007 Jun;120(11):2418-25
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-06-01 / Int. J. Cancer 2007 Jun;120(11):2418-252007-06-01 00:00:002019-02-15 08:49:59Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-05-16 / Lung Cancer 2007 Sep;57(3):365-72
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-05-16 / Lung Cancer 2007 Sep;57(3):365-722007-05-16 00:00:002019-02-15 08:45:36Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-04-19 / Cancer Immunol. Immunother. 2007 Nov;56(11):1817-29
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-04-19 / Cancer Immunol. Immunother. 2007 Nov;56(11):1817-292007-04-19 00:00:002019-02-15 08:48:10DC immunotherapy is highly effective for the inhibition of tumor metastasis or recurrence, although it is not efficient for the eradication of established solid tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-02-09 / Cancer Res 2007 Feb;67(4):1842-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-02-09 / Cancer Res 2007 Feb;67(4):1842-522007-02-09 00:00:002023-03-07 13:12:37Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-02-07 / Cancer Immunol Immunother 2007 Sep;56(9):1485-99
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-02-07 / Cancer Immunol Immunother 2007 Sep;56(9):1485-992007-02-07 00:00:002023-03-07 13:13:36Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers